A MULTINATION PHASE II TRIAL OF BEVACIZUMAB WITH LOW-DOSE INTERFERON-ALPHA2A AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA: BEVLIN СтатьяMelichar B., Bracarda S., Matveev V., Flekseev B., Ivanov S., Zyryanov A., Janciauskiene R., Fernebro E., Mulders P., Osborne S., Jethwa S., Mickisch G., Gore M., R.J.A. Van, Staehler M., Magne N., Bellmunt J.Annals of Oncology. Том V24. 2013.
